Semaglutide Research for Obesity
An evidence-based overview of research examining Semaglutide in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
Semaglutide received FDA approval for chronic obesity management in 2021 based on the comprehensive STEP clinical trial program. The drug achieved substantial weight reduction across diverse populations including those with and without type 2 diabetes. STEP 1 demonstrated that 86.4% of participants achieved clinically meaningful weight loss (5% or more), with 32% achieving 20% or greater reduction. The STEP-HFpEF trial showed benefits in obese patients with heart failure with preserved ejection fraction. The SELECT trial (N=17,604) proved that semaglutide reduces cardiovascular events by 20% in obese individuals with established cardiovascular disease but without diabetes, leading to an additional FDA approval for cardiovascular risk reduction in obesity.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Obesity
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Semaglutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.